Evidence map›Paper›PMID 26206121›Full record

ArticleArchivum immunologiae et therapiae experimentalis2016

Genetic (KIR, HLA-C) and Some Clinical Parameters Influencing the Level of Liver Enzymes and Early Virologic Response in Patients with Chronic Hepatitis C.

Iwona Mozer-Lisewska, Katarzyna Zwolińska, Arleta Elżbieta Kowala-Piaskowska, Maciej Bura, Błażej Rozpłochowski, Anna Pauli, Jan Żeromski, Egbert Piasecki, Piotr Kuśnierczyk

Open access · hybridAbstract read
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Iwona Mozer-LisewskaChair and Department of Infectious Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Katarzyna ZwolińskaLaboratory of Virology, Department of Immunology of Infectious Diseases, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114, Wrocław, Poland. kjzwolinska@iitd.pan.wroc.pl.
Arleta Elżbieta Kowala-PiaskowskaChair and Department of Infectious Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Maciej BuraChair and Department of Infectious Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Błażej RozpłochowskiChair and Department of Infectious Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Anna PauliChair and Department of Infectious Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Jan ŻeromskiChair of Clinical Immunology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland.
Egbert PiaseckiLaboratory of Virology, Department of Immunology of Infectious Diseases, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114, Wrocław, Poland.
Piotr KuśnierczykLaboratory of Immunogenetics and Tissue Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, ul. Rudolfa Weigla 12, 53-114, Wrocław, Poland. pkusnier@iitd.pan.wroc.pl.
Polish Academy of Sciences · PLPoznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer cells play an important role as effectors of innate immunity and regulators of adaptive immunity. They are important elements of the innate response to viral infections, which they detect using human leukocyte antigen (HLA) class I-binding receptors. Most polymorphic of these are killer cell immunoglobulin-like receptors (KIRs) which exist as two basic isotypes, activating or inhibitory receptors and are encoded by genes distributed differently in unrelated individuals. We searched for links between selected clinical data (including HCV viremia, liver enzymes level and liver histology parameters) and the presence of genes encoding these receptors and their ligands in hepatitis C virus-infected individuals subjected to pegylated interferon-α and ribavirin therapy. Genomic DNA samples from two hundred and ninety-two chronically infected patients were typed by polymerase chain reaction for the presence or absence of genes for KIRs and their ligands, class I HLA molecules, and clinical data of the patients were collected. Our results suggest an importance of clinical parameters and the contribution of KIR and HLA genes to the course of hepatitis C virus infection and the response to therapy. The study revealed that levels of liver enzymes before therapy were about 30% higher in patients who possessed a variant KIR2DS4 gene with 22-base pair deletion. Decrease of ALT activity after treatment was higher in HLA-C C2-positive than negative individuals. Beside it, patients demonstrated early virologic response to the therapy if the time lag before treatment was short, particularly in women.

Indexed as

AdultBiomarkers, PharmacologicalFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHepacivirusHepatitis C, ChronicHLA-C AntigensHumansImmunity, InnateImmunotherapyInterferon-alphaKiller Cells, NaturalLiverMaleMiddle AgedBiomarkers, PharmacologicalHLA-C*02 antigenHLA-C AntigensInterferon-alphaKIR2DS4 protein, humanReceptors, KIRRibavirinALTASTEarly virologic responseHCV chronic infectionHLA-C C2KIR2DS4

Identifiers

PMID26206121
PMCPMC4713718
OpenAlexW1921229144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.